Exjade is very costly, so unless Novartis decides to subsidize the cost for Indian patients, it will remain out of the reach of most patients. I think the best hope for exjade in India is if an Indian drug company manufactures their own generic version of it, although we can expect Novartis to try to prevent this from happening by the use of continuing lawsuits.
Kelfer, which has just had its 20th anniversary, remains the only affordable chelator in India at this point in time. For those who can use kelfer, it has been a Godsend, as none of the other chelating drugs has proven to be as effective as kelfer in removing iron from the heart.